The U.S. Food and Drug Administration (FDA) will allow the start of a Phase 2 clinical trial of treatment candidate GKT831 for idiopathic pulmonary fibrosis (IPF). GKT831 is an orally available inhibitor of the NOX1 and NOX4 enzymes, and has been explored for the treatment of liver and kidney…
A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare Diseases (EJP…
Patients older than 75 with idiopathic pulmonary fibrosis (IPF) are at higher risk of discontinuing treatment with Esbriet (pirfenidone) due to adverse reactions, namely anorexia, according to a retrospective analysis made in Japan. The study, “Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis,”…
Gilead Sciences gained rights over GLPG1690, Galapagos‘ investigational therapy for idiopathic pulmonary fibrosis (IPF), as part of a 10-year research collaboration between the two companies. The agreement will allow Gilead to have access to Galapagos’ therapeutic platform, which includes six molecules currently in clinical trials, and more than…
The demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis (IPF) in Spain are similar to those of IPF patients in other countries, allowing for comparison with other registries and cohorts, a study has found. The study, “Demographic and Clinical Profile of Idiopathic Pulmonary Fibrosis Patients in…
The Alpha Foundation for the Improvement of Mining Safety and Health has granted $750,000 to a project to investigate how silica, coal, and other mining dusts contribute to the development of progressive lung fibrosis. Led by researchers at the Chicago Mining Education and Research (MinER) Center from the…
Lack of tissue oxygenation, also known as hypoxia, is involved in the development and progression of idiopathic pulmonary fibrosis (IPF), a study has found. The findings of the study, “Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis,” were published in the journal Respiratory Research.
NP-120, Algernon Pharmaceuticals‘ repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), surpassed two other globally approved therapies — Genentech‘s Esbriet (pirfenidone) and Boehringer Ingelheim‘s Ofev (nintedanib) — in reducing lung tissue scarring (fibrosis) in a mouse model of IPF. Current guidelines…
The Assistance Fund, an independent and charitable foundation, announced that it has launched a new copay assistance program to support people with idiopathic pulmonary fibrosis (IPF). Also known as TAF, the fund provides financial support to patients and families facing high medical out-of-pocket costs by partly covering co-payments, co-insurance,…
It wasn’t until Gordana Loleska’s son David was 14 years old that doctors in their native North Macedonia diagnosed his kidney, vision, and hearing problems as Alport syndrome. Although she had known for years that something was wrong, the news that David would battle a lifelong rare disease devastated…
Get regular updates to your inbox.
